TransMedics Group, Inc. Research and Development Expense
TransMedics Group, Inc. (TMDX) reported Research and Development Expense of $31.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- TransMedics Group, Inc. research and development expense for the quarter ending 2026-06-30 was $31.63M, a 98.52% increase year-over-year.
- TransMedics Group, Inc. research and development expense for the quarter ending 2026-03-31 was $24.88M, a 44.98% increase year-over-year.
- TransMedics Group, Inc. research and development expense for the quarter ending 2025-12-31 was $20.70M, a 25.73% increase year-over-year.
- TransMedics Group, Inc. research and development expense for the quarter ending 2025-09-30 was $15.26M, a 6.97% increase year-over-year.
- TransMedics Group, Inc. research and development expense for fiscal 2025 was $69.06M, a 23.38% increase from fiscal 2024.
- TransMedics Group, Inc. research and development expense for fiscal 2024 was $55.97M, a 55.23% increase from fiscal 2023.
- TransMedics Group, Inc. research and development expense for fiscal 2023 was $36.05M, a 34.47% increase from fiscal 2022.
- TransMedics Group, Inc. research and development expense for fiscal 2022 was $26.81M, a 20.21% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.63M 10-Q · filed 2026-08-04 | $56.51M 10-Q · filed 2026-08-04 | $77.21M derived: sum of 3 quarters · filed 2026-08-04 | $92.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $24.88M 10-Q · filed 2026-05-05 | $45.58M derived: sum of 2 quarters · filed 2026-05-05 | $60.84M derived: sum of 3 quarters · filed 2026-05-05 | $76.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $35.96M derived: sum of 2 quarters · filed 2026-02-24 | $51.90M derived: sum of 3 quarters · filed 2026-08-04 | $69.06M 10-K · filed 2026-02-24 |
| 2025-09-30 | $15.26M 10-Q · filed 2025-10-29 | $31.19M derived: sum of 2 quarters · filed 2026-08-04 | $48.35M 10-Q · filed 2025-10-29 | $64.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $15.93M 10-Q · filed 2026-08-04 | $33.09M 10-Q · filed 2026-08-04 | $49.56M derived: sum of 3 quarters · filed 2026-08-04 | $63.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $17.16M 10-Q · filed 2026-05-05 | $33.62M derived: sum of 2 quarters · filed 2026-05-05 | $47.89M derived: sum of 3 quarters · filed 2026-05-05 | $61.75M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $16.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $30.73M derived: sum of 2 quarters · filed 2026-02-24 | $44.59M derived: sum of 3 quarters · filed 2026-02-24 | $55.97M 10-K · filed 2026-02-24 |
| 2024-09-30 | $14.27M 10-Q · filed 2025-10-29 | $28.12M derived: sum of 2 quarters · filed 2025-10-29 | $39.50M 10-Q · filed 2025-10-29 | $50.27M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $13.86M 10-Q · filed 2025-07-30 | $25.24M 10-Q · filed 2025-07-30 | $36.00M derived: sum of 3 quarters · filed 2026-02-24 | $47.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $11.38M 10-Q · filed 2025-05-08 | $22.14M derived: sum of 2 quarters · filed 2026-02-24 | $33.27M derived: sum of 3 quarters · filed 2026-02-24 | $41.56M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $10.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $21.89M derived: sum of 2 quarters · filed 2026-02-24 | $30.18M derived: sum of 3 quarters · filed 2026-02-24 | $36.05M 10-K · filed 2026-02-24 |
| 2023-09-30 | $11.13M 10-Q · filed 2024-10-29 | $19.42M derived: sum of 2 quarters · filed 2024-10-29 | $25.29M 10-Q · filed 2024-10-29 | $31.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $8.29M 10-Q · filed 2024-08-01 | $14.16M 10-Q · filed 2024-08-01 | $19.92M derived: sum of 3 quarters · filed 2025-02-27 | $26.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.87M 10-Q · filed 2024-05-02 | $11.63M derived: sum of 2 quarters · filed 2025-02-27 | $18.43M derived: sum of 3 quarters · filed 2025-02-27 | $25.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $12.56M derived: sum of 2 quarters · filed 2025-02-27 | $19.28M derived: sum of 3 quarters · filed 2025-02-27 | $26.81M 10-K · filed 2025-02-27 |
| 2022-09-30 | $6.81M 10-Q · filed 2023-11-08 | $13.52M derived: sum of 2 quarters · filed 2023-11-08 | $21.06M 10-Q · filed 2023-11-08 | $27.37M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $6.71M 10-Q · filed 2023-08-04 | $14.25M 10-Q · filed 2023-08-04 | $20.56M derived: sum of 3 quarters · filed 2024-02-27 | $25.73M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $7.53M 10-Q · filed 2023-05-04 | $13.85M derived: sum of 2 quarters · filed 2024-02-27 | $19.01M derived: sum of 3 quarters · filed 2024-02-27 | $25.31M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $11.48M derived: sum of 2 quarters · filed 2024-02-27 | $17.77M derived: sum of 3 quarters · filed 2024-02-27 | $22.30M 10-K · filed 2024-02-27 |
| 2021-09-30 | $5.16M 10-Q · filed 2022-11-04 | $11.46M derived: sum of 2 quarters · filed 2022-11-04 | $15.99M 10-Q · filed 2022-11-04 | $20.54M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $6.29M 10-Q · filed 2022-08-03 | $10.83M 10-Q · filed 2022-08-03 | $15.38M derived: sum of 3 quarters · filed 2023-02-27 | $19.53M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $4.53M 10-Q · filed 2022-05-05 | $9.08M derived: sum of 2 quarters · filed 2023-02-27 | $13.23M derived: sum of 3 quarters · filed 2023-02-27 | $17.14M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $8.70M derived: sum of 2 quarters · filed 2023-02-27 | $12.61M derived: sum of 3 quarters · filed 2023-02-27 | $18.83M 10-K · filed 2021-03-11 |
| 2020-09-30 | $4.16M 10-Q · filed 2021-11-09 | $8.06M derived: sum of 2 quarters · filed 2021-11-09 | $14.28M 10-Q · filed 2021-11-09 | $20.55M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $3.90M 10-Q · filed 2021-08-06 | $10.13M 10-Q · filed 2021-08-06 | $16.39M derived: sum of 3 quarters · filed 2021-08-06 | $21.33M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $6.22M 10-Q · filed 2021-05-07 | $12.49M derived: sum of 2 quarters · filed 2021-05-07 | $17.43M derived: sum of 3 quarters · filed 2021-05-07 | $22.21M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-28 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $11.20M derived: sum of 2 quarters · filed 2021-03-11 | $15.99M derived: sum of 3 quarters · filed 2021-03-11 | $19.87M 10-K · filed 2021-03-11 |
| 2019-09-28 | $4.94M 10-Q · filed 2020-11-06 | $9.73M derived: sum of 2 quarters · filed 2020-11-06 | $13.61M 10-Q · filed 2019-11-08 | |
| 2019-06-29 | $4.79M 10-Q · filed 2020-08-07 | $8.67M 10-Q · filed 2020-08-07 | ||
| 2019-03-30 | $3.88M 10-Q · filed 2020-05-06 | |||
| 2018-12-29 | $13.66M 10-K · filed 2020-03-17 | |||
| 2018-09-29 | $3.27M 10-Q · filed 2019-11-08 | $6.71M derived: sum of 2 quarters · filed 2019-11-08 | $10.17M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $3.43M 10-Q · filed 2019-08-08 | $6.90M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $3.46M 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |